Litcius/Paper detail

Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial

Willem Brandt, Cameron Brown, Tzu‐Fei Wang, Vicky Tagalakis, Sudeep Shivakumar, L.A. Ciuffini, Ranjeeta Mallick, Philip S. Wells, Marc Carrier

2022Thrombosis Research24 citationsDOI

Topics & Concepts

MedicineApixabanVenous thromboembolismSubgroup analysisIntensive care medicineCentral venous catheterInternal medicineClinical trialCatheterCancerOncologySurgeryMeta-analysisThrombosisRivaroxabanWarfarinAtrial fibrillationVenous Thromboembolism Diagnosis and ManagementCentral Venous Catheters and HemodialysisChemotherapy-related skin toxicity
Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial | Litcius